LLY

1,030.81

-1.91%↓

JNJ

248.28

-0.06%↓

ABBV

232.5

+0.22%↑

NVS

166.42

-1.13%↓

MRK

121.73

-1.61%↓

LLY

1,030.81

-1.91%↓

JNJ

248.28

-0.06%↓

ABBV

232.5

+0.22%↑

NVS

166.42

-1.13%↓

MRK

121.73

-1.61%↓

LLY

1,030.81

-1.91%↓

JNJ

248.28

-0.06%↓

ABBV

232.5

+0.22%↑

NVS

166.42

-1.13%↓

MRK

121.73

-1.61%↓

LLY

1,030.81

-1.91%↓

JNJ

248.28

-0.06%↓

ABBV

232.5

+0.22%↑

NVS

166.42

-1.13%↓

MRK

121.73

-1.61%↓

LLY

1,030.81

-1.91%↓

JNJ

248.28

-0.06%↓

ABBV

232.5

+0.22%↑

NVS

166.42

-1.13%↓

MRK

121.73

-1.61%↓

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atidarymo kaina

17.48 -4.32

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.02

Max

18.27

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+74.15% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	869M 1.4B
Ankstesnė atidarymo kaina	21.8
Ankstesnė uždarymo kaina	17.48

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-01 23:35; UTC

Svarbiausios naujienos

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026-03-01 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026-03-01 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026-03-01 23:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026-03-01 23:39; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-01 23:39; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026-03-01 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026-03-01 23:24; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-01 23:24; UTC

Rinkos pokalbiai

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026-03-01 23:21; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-01 23:21; UTC

Rinkos pokalbiai

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026-03-01 23:19; UTC

Svarbiausios naujienos

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026-03-01 23:17; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026-03-01 23:14; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026-03-01 22:55; UTC

Svarbiausios naujienos

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026-03-01 22:54; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026-03-01 22:53; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026-03-01 22:38; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026-03-01 22:21; UTC

Uždarbis

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026-03-01 22:17; UTC

Rinkos pokalbiai

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026-03-01 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026-03-01 22:00; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026-03-01 21:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026-03-01 21:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026-03-01 21:30; UTC

Rinkos pokalbiai

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026-03-01 21:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026-03-01 21:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026-03-01 20:58; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026-03-01 20:40; UTC

Rinkos pokalbiai

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026-03-01 20:24; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

74.15% į viršų

12 mėnesių prognozė

Vidutinis 31.8 USD 74.15%

Aukščiausias 42 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.